World's Best Scientists 2026 revealed!
Jean-Jacques Grob

Jean-Jacques Grob

D-Index & Metrics

Medicine

D-Index
103
Citations
86496
World Ranking
7148
National Ranking
219

Jean-Jacques Grob publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jean-Jacques Grob sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 529 publications — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jean-Jacques Grob D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jean-Jacques Grob sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jean-Jacques Grob is affiliated with Aix-Marseille University in France. Their primary research focus lies within the broad field of Medicine, with significant contributions to Oncology, Molecular Biology, Epidemiology, Immunology, and Dermatology.

The scientist's work encompasses various topics related to cancer and immune system research including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Nonmelanoma Skin Cancer Studies
  • Immunotherapy and Immune Responses
  • Cutaneous lymphoproliferative disorders research

Jean-Jacques Grob has authored numerous papers, contributing to the academic literature with a focus on melanoma and immunotherapy. Some of their recent publications include:

  • "Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)," 2020, Journal of Clinical Oncology

While Jean-Jacques Grob authored key clinical trial work in the area of immune checkpoint inhibitors, it is notable that several frequently cited melanoma and immunotherapy papers in their network include:

  • "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma," 2022, Zurich Open Repository and Archive (University of Zurich)
  • "Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial," 2021, The Lancet Oncology
  • "Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial," 2020, Journal of Clinical Oncology
  • "European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022," 2022, European Journal of Cancer

Jean-Jacques Grob frequently collaborates with several coauthors, notable for repeated joint publications, including:

  • Georgina V. Long
  • Paolo A. Ascierto
  • Dirk Schadendorf
  • Caroline Robert
  • Célèste Lebbe

The scientist's publications are commonly featured in well-known oncology and dermatology journals such as:

  • Journal of Clinical Oncology
  • European Journal of Cancer
  • Annals of Oncology
  • Annales de Dermatologie et de Vénéréologie
  • Annales de Dermatologie et de Vénéréologie - FMC

Best Publications

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

    Mark R Middleton;J J Grob;N Aaronson;G Fierlbeck

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

    Jedd D Wolchok;Bart Neyns;Gerald Linette;Sylvie Negrier

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

    Frank Stephen Hodi;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Jacob Schachter;Antoni Ribas;Georgina V. Long;Ana Arance

  • Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

    Georgina V Long;Reinhard Dummer;Omid Hamid;Thomas F Gajewski

  • Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Caroline Robert;Antoni Ribas;Jacob Schachter;Ana Arance

  • The role of BRAF V600 mutation in melanoma

    Paolo A. Ascierto;John M. Kirkwood;Jean Jacques Grob;Ester Simeone

Frequent Co-Authors

Caroline Robert
Caroline Robert University of Paris-Saclay
Georgina V. Long
Georgina V. Long University of Sydney
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Axel Hauschild
Axel Hauschild Kiel University
Céleste Lebbé
Céleste Lebbé Hôpitaux Universitaires Paris-Ouest
Piotr Rutkowski
Piotr Rutkowski Maria Sklodowska-Curie National Research Institute of Oncology
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Vanna Chiarion-Sileni
Vanna Chiarion-Sileni European Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students exploring a future in medicine, a range of online degrees and alternative career pathways are available in the USA. Each offers distinct entry requirements, study durations, and career outcomes, making it important to choose an option that aligns with your personal and professional goals.

Nursing remains one of the most accessible fields, with several nursing schools that don't require teas test. This can streamline admissions for aspiring nurses seeking flexibility or facing exam barriers.

For those interested in the administrative side of healthcare, a health care administration degree online offers an accelerated path to leadership roles in hospitals, clinics, and public health organizations.

Nurses looking to advance can bridge from associate to graduate-level practice with asn to np programs, opening opportunities as nurse practitioners and specialized clinicians.

Nutrition is another vital healthcare field. A flexible option for those interested in dietetics or wellness coaching is a bachelor's in nutrition online, allowing study and professional development on your own schedule.

Best Scientists Citing Jean-Jacques Grob

Trending Scientists

Recently Published Articles